Actinogen Showcases Alzheimer’s Drug at ADRF 2024
Company Announcements

Actinogen Showcases Alzheimer’s Drug at ADRF 2024

Actinogen Medical Limited (AU:ACW) has released an update.

Actinogen Medical showcases its innovative Alzheimer’s treatment, Xanamem, at the Australian Dementia Research Forum 2024. The company’s poster detailed the drug’s dose selection process and its potential to improve cognition and slow disease progression in Alzheimer’s patients. Actinogen is currently conducting clinical trials to further validate Xanamem’s efficacy as a treatment for neurological and neuropsychiatric diseases.

For further insights into AU:ACW stock, check out TipRanks’ Stock Analysis page.

Looking for more investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!